{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-078937","form_type":"8-K","ticker":"RAPH","cik":"0001415397","company_name":"Raphael Pharmaceutical Inc.","filed_at":"2026-07-17T13:20:50+00:00","discovered_at":"2026-07-17T13:22:00.361867+00:00","generated_at":"2026-07-17T13:22:04.930380+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Chairman and CFO resign; Uri Tadelis appointed as new CFO","bullets":["Ajay Kumar Dhadha resigned as Chairman and Director effective June 30, 2026.","Guy Ofir resigned as CFO, General Counsel, and Director effective July 16, 2026.","Both resignations were not due to any disagreement with the company.","Uri Tadelis appointed as CFO effective July 16, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-078937","json":"https://secwatch.observer/filing/0001213900-26-078937.json","markdown":"https://secwatch.observer/filing/0001213900-26-078937.md","text":"https://secwatch.observer/filing/0001213900-26-078937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1415397/000121390026078937/0001213900-26-078937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1415397/000121390026078937/ea0298326-8k_raphael.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-17T13:22:04.930380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"202aaaabac","claim":"Ajay Kumar Dhadha resigned as Chairman of the Board of Directors at Raphael Pharmaceutical Inc..","evidence_excerpt":"Mr. Ajay Kumar Dhadha voluntarily resigned from his positions as Chairman of the Board of Directors and Director of the Company, effective June 30, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1415397/000121390026078937/0001213900-26-078937-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"218017ef98","claim":"Guy Ofir resigned as Chief Financial Officer, General Counsel, and Director at Raphael Pharmaceutical Inc..","evidence_excerpt":"Mr. Guy Ofir voluntarily resigned from his positions as Chief Financial Officer, General Counsel, and Director of the Company, effective July 16, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1415397/000121390026078937/0001213900-26-078937-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer, General Counsel, and Director"}],"fact_type":"executive_change"},{"claim_id":"c8e3e1ea8e","claim":"Uri Tadelis was appointed as Chief Financial Officer at Raphael Pharmaceutical Inc..","evidence_excerpt":"Effective July 16, 2026, the Company appointed Mr. Uri Tadelis as its Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1415397/000121390026078937/0001213900-26-078937-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}